{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.","id":"OG000","title":"Bexarotene + GM-CSF"}],"populationDescription":"Due to the limited number of clinical responders, this research assay was not done.","reportingStatus":"POSTED","timeFrame":"Baseline and 6, 12, 24, and 36 weeks","title":"Biological Activity as Measured by in Vivo Induction of Terminal Differentiation of Myeloid Progenitors and in Vivo Changes in Detectable Chromosomal Abnormalities","type":"SECONDARY"}